TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00194870

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EEG
Description: computer-assisted analysis of the digitally-recorded EEG signals
Study: NCT00475982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Weight Loss Group
Description: These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
Study: NCT01205867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
Study: NCT00597896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole
Description: po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pramipexole
Description: po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
Study: NCT04772833

Intervention type: OTHER
Intervention: Autopsy
Description: The subjects deceased will undergo an autopsy to analyze the histopathological, ultrastructural and microbiological findings, related to the COVID-19 disease.
Study: NCT03730142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WXFL10030390
Description: WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
Study: NCT04771091

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mesure of head-perineum distance by transperineal ultrasound
Description: A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
Study: NCT02920099

Intervention type: OTHER
Intervention: Nutrition Literacy Assessment Instrument (NLAI)
Description: Assessment tool which combines elements of different nutrition literacy tools.
Study: NCT02282241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01895621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Median nerve decompression at the wrist
Description: Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Median nerve decompression at the wrist
Description: Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid post median nerve decompression
Description: Daily supplementation of alpha lipoic acid
Study: NCT01097408

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo capsules
Study: NCT00590395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18FDG (an FDA-approved radiopharmaceutical)
Description: Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
Study: NCT00783198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641 6 Amb a 1-U
Description: SCH 39641 6 Amb a 1-U sublingual tablets administered once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641 12 Amb a 1-U
Description: SCH 39641 12 Amb a 1-U sublingual tablets administered once daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo sublingual tablets administered once daily
Study: NCT03386838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Administered 100mg orally once daily for a maximum of 104 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
Study: NCT01801267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Description: Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular shunt
Description: Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
Study: NCT00575484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline, then oral sodium chloride
Description: 2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline, then oral placebo capsule
Description: 20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
Study: NCT00301613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF,1.0g/d
Study: NCT00444561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramlintide acetate
Description: Clear, colorless, sterile solution for SC administration
Study: NCT03268655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger extract
Description: 2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
Study: NCT02692391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
Study: NCT01433380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
Study: NCT02654717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-07 Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study: NCT01316198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum
Description: 10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
Study: NCT02541149

Intervention type: PROCEDURE
Intervention: blood sample

Intervention type: PROCEDURE
Intervention: blood sample
Study: NCT00539188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
Study: NCT03288051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management
Description: Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management
Description: Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
Study: NCT04832269

Intervention type: OTHER
Intervention: Exposure to methylprednisolone during pregnancy
Description: Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
Study: NCT03722277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variable load training
Description: Based on symptoms/strength measured in an isometric maximum strength test at five different angles of knee flexion- and extension, participants will be training with variable load during both concentric and excentric phase of the dynamic movement. Initially participants will start at 40% of symptom limited isometric strength, this will increase to 50% during the training period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional strength training
Description: Conventional strength training with rubber bands in knee flexion- and extension, additionally hip abduction- and adduction.
Study: NCT06244290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate SNF
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate SNF
Description: toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate SNF
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Extra Whitening
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Extra Whitening
Description: toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sensodyne Extra Whitening
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Fluoride (CDC)
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Fluoride (CDC)
Description: toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Fluoride (CDC)
Description: toothpaste
Study: NCT03868527

Intervention type: OTHER
Intervention: Data collection
Description: Data collection for biostatistical analysis about hematological diseases
Study: NCT01685151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL (Dose 1)
Description: Ramelteon tablets for sublingual administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL (Dose 2)
Description: Ramelteon tablets for sublingual administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04139993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbiota-based Formulation RBX7455
Description: Given PO
Study: NCT03297905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary and Integrative Therapies
Description: Intervention time period is 3 - 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitative Care
Description: Intervention time period is 3 - 6 weeks.
Study: NCT02401425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04363541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric pad for human external pain therapy
Description: An electric pad for local heat production will be put on the back of the patient for two hours
Study: NCT00899392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emmi Pediatric Upper Endoscopy Patient Education Module
Description: Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
Study: NCT02185924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%
Study: NCT02541149

Intervention type: PROCEDURE
Intervention: blood sample
Study: NCT00731926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligomerized litchi fruit extract
Description: 100mg at once twice a day for 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VItamin C + Vitamin E mixture
Description: Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
Study: NCT02185924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N/S 0.9%
Study: NCT04194385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper trunk block
Description: Block will be applied to supraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Costoclavicular block
Description: Block will be applied to infraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic function assessment
Description: Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic function assessment
Description: Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical plexus blockade
Description: Block will be applied at thyroid cartilage level via 10 ml % 0.25 bupivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical plexus blockade
Description: Block will be applied at thyroid cartilage level via 10 ml % 0.25 bupivacaine.
Study: NCT01536392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of 3 questionnaires at study visits taking about 5 minutes each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of 3 questionnaires at study visits taking about 5 minutes each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Drug Diary
Description: Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Drug Diary
Description: Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
Study: NCT04942977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: The system consists of the following elements:~1. Professional website at the hospital, which allows:~   * To set up an individualised care plan~  * To establish the patient's risk profile and targets for improvement.~  * Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred~  * Advise the patient on self-management strategies.~2. Mobile application software with the following functions:~   * Scheduled exercise sessions~  * Medication reminder~  * Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.)~  * Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~  * Training monitor: guides the patient in the performance of their exercise.~  * Access to certified health information for patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centre-based cardiac rehabilitation
Description: The physical activity consisted of a workout routine and aerobic cycling training. Patients are instructed to perform 150 minutes per week of moderate physical activity when the hospital phase finishes.
Study: NCT01573234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MySkin patch
Description: Hydrogel and polyurethane film

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze and Patch
Description: Traditional Dressing
Study: NCT03753789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
Study: NCT02928263

Intervention type: OTHER
Intervention: Non-Interventional
Description: Other

Intervention type: OTHER
Intervention: Non-Interventional
Description: Other
Study: NCT03339154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
Study: NCT01269242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bindarit
Description: 300 mg bid, that is one 300 mg tablet twice a day for 6 months;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bindarit
Description: 600 mg bid, that is two 300 mg tablets twice a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: bindarit-matching placebo tablets for 6 months.
Study: NCT02766140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1020 plus Docetaxel
Description: SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Docetaxel
Description: Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
Study: NCT01526824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids (Lovaza)
Description: Lovaza, 1 gram orally daily
Study: NCT04520438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukocyte and platelet rich fibrin
Description: L-PRF membrane and irrigation with L-PRF exudate in the same treatment session of NSPT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical Periodontal treatment
Description: The control group only received NSPT (scaling and root planing) in one treatment session.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-Surgical Periodontal treatment
Description: The control group only received NSPT (scaling and root planing) in one treatment session.
Study: NCT01578850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept 50mg once weekly + methotrexate with or without other DMARDs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: etanercept placebo once weekly + methotrexate with or without other DMARDs
Study: NCT01494623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain regions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain regions.
Study: NCT01630993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
Study: NCT00263185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium carbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02923440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample